School of Medicine

Wayne State University School of Medicine

GALA- Study Evaluating Low-Frequency Administration of Copaxone - Closed to Enrollment

This is a multi-center study to evaluate the efficacy, safety, and tolerability of glatiramer acetate (Copaxone®) 40mg compared to placebo. Patients will be randomized to receive either Copaxone® 40mg subcutaneous injections 3 times a week or matching placebo 3 times a week. The study duration will be 12 months with the possibility of an open label study extension.

Eligibility: Patients must be 18-55 yrs old diagnosed with relapsing-remitting MS, who are able to walk at least 100 meter without aid or help. Patients must have one documented relapse in the past 12 months, or two documented relapses in the past 24 months.
For more information visit: GALA